Last $27.59 USD
Change Today +0.48 / 1.77%
Volume 136.1K
As of 8:10 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Snapshot

Open
$26.77
Previous Close
$27.11
Day High
$27.76
Day Low
$25.92
52 Week High
10/30/13 - $42.00
52 Week Low
11/14/13 - $18.10
Market Cap
926.6M
Average Volume 10 Days
259.5K
EPS TTM
$-0.44
Shares Outstanding
33.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPIZYME INC (EPZM)

epizyme inc (EPZM) Related Businessweek News

No Related Businessweek News Found

epizyme inc (EPZM) Details

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors. The company has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

74 Employees
Last Reported Date: 02/28/14
Founded in 2007

epizyme inc (EPZM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $564.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $487.5K
Chief Medical Officer
Total Annual Compensation: $463.5K
Advisor
Total Annual Compensation: $513.2K
Compensation as of Fiscal Year 2013.

epizyme inc (EPZM) Key Developments

Epizyme, Inc. Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma

Epizyme, Inc. presented pre-clinical data on EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects young adults. Synovial sarcomas are characterized by a translocation of chromosomes X and 18, generating an SS18-SSX fusion protein that creates a state of deficiency of the INI1 protein. The data were presented by Heike Keilhack, Ph.D., Director of Biological Sciences, Epizyme, during the annual meeting of the Connective Tissue Oncology Society, held October 15-18 in Berlin, Germany. In the study, synovial sarcoma cell lines and patient-derived xenograft models were evaluated for their sensitivity to EZH2 inhibition in vitro and in vivo. Histone methylation, changes in gene expression and histology endpoints were also assessed. The data showed that EPZ-6438 induced dose-dependent inhibition of cell growth and cell death specifically in SS18-SSX fusion-positive cells in vitro. Treatment of mice with either a cell line xenograft or two patient-derived xenograft models led to dose-dependent tumor growth inhibition, while treatment in a fourth xenograft model did not reflect such results.

Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium

Epizyme, Inc. announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, will be featured in a late-breaking oral presentation at the 26(th) EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain. The presentation will take place during the plenary session on Epigenetic Targets. In addition, this session will feature a presentation from Chief Scientific Officer Robert Copeland, Ph.D., discussing Epizyme's targeted therapies against the histone methyltransferases (HMTs) DOT1L and EZH2. Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma.

Epizyme Seeks Acquisitions

Epizyme, Inc. (NasdaqGS:EPZM) is looking forward to contributing to its future success through strategic partnerships.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $27.59 USD +0.48

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies
 

Industry Analysis

EPZM

Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.3x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.